Abstract:One of the neuropathological hallmarks of Alzheimer's disease is the presence of β-amyloid (Aβ)-containing neuritic plaques. Aβ is produced by the proteolytic cleavage of the amyloid precursor protein by β- and γ-secretase enzymes. Thus, inhibition of β-secretase (BACE1) is a promising disease modifying approach for the treatment of Alzheimer's disease. Identification of orally-bioavailable, CNS-active small molecule BACE inhibitors is challenging. SCH 785532 is a novel, potent, non-peptidic, orally available and brain penetrant BACE inhibitor. Following acute administration in pre-plaque transgenic CRND8 (TgCRND8) mice over-expressing human amyloid precursor protein with two familial Alzheimer's disease mutations, SCH 785532 produced robust inhibition of plasma Aβ but only modestly reduced cortical Aβ levels. This study sought to determine if chronic treatment with this BACE inhibitor would reduce cortical Aβ levels as well as to assess the disease modifying potential of chronic BACE inhibition as measured by a reduction in plaque deposition and/or improvement in cognitive performance. Beginning at 6 weeks of age (pre-plaque), TgCRND8 mice were treated with vehicle or SCH 785532 (100 mg/kg/day, in diet) for 6, 12, 18 or 24 weeks (well into the plaque deposition period). This dose given in diet provided relatively constant exposure and robust inhibition of plasma Aβ. Following 12-24 weeks of treatment, SCH 785532 reduced total guanidine extracted cortical Aβ40 and Aβ42 levels by 30%. While total β-amyloid plaque burden was not dramatically changed with SCH 785532 treatment, mature Thioflavine S positive fibrillar Aβ containing plaques were reduced by 35% after 24 weeks of treatment. Increased microglia reactivity observed around Aβ plaques was not noticeably reduced by 24 weeks of treatment with SCH 785532. TgCRND8 mice treated with vehicle did not perform as well as non-transgenic vehicle-treated mice in the Morris water maze and 24 weeks of treatment with SCH 785532 moderately improved performance of the transgenic mice in this cognition model. Overall, the results of this study demonstrate that chronic BACE inhibition reduced brain Aβ levels, delayed the maturation of amyloid plaques, improved cognitive function and was well tolerated. This study provides support that inhibition of BACE may have disease-modifying potential in the clinic.

Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D

Early Inhibition of Phosphodiesterase 4B (PDE4B) Instills Cognitive Resilience in APPswe/PS1dE9 Mice

Protective effect of PDE4B subtype-specific inhibition in an App knock-in mouse model for Alzheimer's disease

Phosphodiesterase-4d Knock-Out And Rna Interference-Mediated Knock-Down Enhance Memory And Increase Hippocampal Neurogenesis Via Increased Camp Signaling

Protection from Amyloid Β Peptide–Induced Memory, Biochemical, and Morphological Deficits by a Phosphodiesterase-4D Allosteric Inhibitor

Memory impairments in Tg19959 and APP/PS1 AD model mice are alleviated by eEF2K inhibitor A‐484954

Beneficial effects of physical exercise and an orally active mGluR2/3 antagonist pro-drug on neurogenesis and behavior in an Alzheimer's amyloidosis model

Inhibition Of Phosphodiesterase-4 Reverses Memory Deficits Produced By A Beta 25-35 Or A Beta 1-40 Peptide In Rats

P2‐359: Cathepsin B Gene Deletion or Inhibition Improves Memory Deficits in a Mouse Model of Alzheimer's Disease Expressing APP with the Wild‐type Beta‐secretase Site

P3‐299: Chronic Administration of a Novel BACE Inhibitor Reduced Brain Aβ Levels and Mature Plaques and Modestly Improved Cognition in Transgenic CRND8‐APPswe/ind Mice

Pridopidine Promotes Synaptogenesis and Reduces Spatial Memory Deficits in the Alzheimer's Disease APP/PS1 Mouse Model

Altered phosphorylation, electrophysiology, and behavior on attenuation of PDE4B action in hippocampus

A Polyaminobiaryl-Based β-secretase Modulator Alleviates Cognitive Impairments, Amyloid Load, Astrogliosis, and Neuroinflammation in APPSwe/PSEN1ΔE9 Mice Model of Amyloid Pathology

Edaravone Dexborneol ameliorates the cognitive deficits of APP/PS1 mice by inhibiting TLR4/MAPK signaling pathway via upregulating TREM2

Target Engagement Of A Phosphodiesterase 2a Inhibitor Affecting Long-Term Memory In The Rat

BAY 73-6691 Alters Neuron Plasticity and Phosphorylation of Tau Through Regulation of Cyclic Guanosine Monophosphate/Protein Kinase G/Cyclic Adenosine Monophosphate Response Element-Binding Protein Pathway

DL0410 can reverse cognitive impairment, synaptic loss and reduce plaque load in APP/PS1 transgenic mice

((<i>E</i>)-<i>N</i>-(4-(((2-Amino-5-phenylpyridin-3-yl)imino)methyl)pyr idin-2-yl)cyclopropanecarboxamide) Ameliorated A<sub>1-42</sub>-Induced Alzheimer's Disease in SD Rats by Inhibiting Oxidative Stress and Apoptosis

P4-364 Rapid In-Vivo Assessment of Therapeutic Window of Two Γ-Secretase Inhibitors in Transgenic CRND8 Mice

Protective effects of phosphodiesterase 2 inhibitor against Aβ1-42 induced neuronal toxicity

Effects of BIS-MEP on Reversing Amyloid Plaque Deposition and Spatial Learning and Memory Impairments in a Mouse Model of Β-Amyloid Peptide- and Ibotenic Acid-Induced Alzheimer’s Disease